We developed a clinically applicable IHC assay to spatially assess SLFN11 expression patterns and prevalence across multiple tumour types and elucidated the role of SLFN11 as a potential biomarker of PARP inhibitor drug sensitivity. The gene discussed is SLFN11; the disease is neoplasm.